SAMC
ABBV icon

Spectrum Asset Management (California)’s AbbVie ABBV Stock Holding History

Spectrum Asset Management (California)’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.94M Buy
18,130
+45
+0.2% +$9.98K 1.25% 25
2025
Q4 		$4.13M Sell
18,085
-2,472
-12% -$563K 1.38% 24
2025
Q3 		$4.76M Sell
20,557
-53
-0.3% -$10.8K 1.67% 17
2025
Q2 		$3.83M Sell
20,610
-236
-1% -$43.9K 1.66% 24
2025
Q1 		$4.37M Sell
20,846
-26
-0.1% -$5.05K 1.94% 19
2024
Q4 		$3.71M Sell
20,872
-1,197
-5% -$220K 1.67% 21
2024
Q3 		$4.36M Sell
22,069
-101
-0.5% -$18.9K 1.84% 17
2024
Q2 		$3.8M Buy
22,170
+704
+3% +$117K 1.76% 19
2024
Q1 		$3.91M Sell
21,466
-480
-2% -$82.7K 1.68% 22
2023
Q4 		$3.4M Sell
21,946
-649
-3% -$94.6K 1.51% 24
2023
Q3 		$3.37M Sell
22,595
-493
-2% -$72.4K 1.77% 21
2023
Q2 		$3.11M Sell
23,088
-2,395
-9% -$351K 1.55% 21
2023
Q1 		$4.06M Sell
25,483
-238
-0.9% -$36.4K 2.01% 12
2022
Q4 		$4.16M Buy
25,721
+401
+2% +$61.5K 2.02% 13
2022
Q3 		$3.4M Buy
25,320
+1,221
+5% +$175K 1.74% 13
2022
Q2 		$3.69M Buy
24,099
+1
+0% +$153 1.82% 10
2022
Q1 		$3.91M Buy
24,098
+52
+0.2% +$7.55K 1.53% 20
2021
Q4 		$3.26M Sell
24,046
-3,689
-13% -$436K 0.92% 29
2021
Q3 		$2.99M Sell
27,735
-125
-0.4% -$14.3K 0.92% 33
2021
Q2 		$3.14M Sell
27,860
-1,100
-4% -$124K 0.94% 36
2021
Q1 		$3.13M Sell
28,960
-240
-0.8% -$25.7K 0.97% 31
2020
Q4 		$3.13M Sell
29,200
-1,305
-4% -$125K 1.12% 23
2020
Q3 		$2.67M Sell
30,505
-130
-0.4% -$12.2K 1.12% 20
2020
Q2 		$3.01M Sell
30,635
-2,575
-8% -$227K 1.55% 15
2020
Q1 		$2.53M Buy
33,210
+595
+2% +$50.7K 2.41% 9
2019
Q4 		$2.89M Sell
32,615
-700
-2% -$58.1K 1.59% 18
2019
Q3 		$2.52M Buy
33,315
+23,475
+239% +$1.61M 1.62% 17
2019
Q2 		$716K Hold
9,840
– – 0.45% 60
2019
Q1 		$793K Sell
9,840
-20
-0.2% -$1.64K 0.53% 58
2018
Q4 		$909K Sell
9,860
-4,000
-29% -$352K 0.72% 49
2018
Q3 		$1.31M Buy
+13,860
New +$1.31M 0.78% 43

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Spectrum Asset Management (California)'s ABBV Position: Q1 2026 in Review

Spectrum Asset Management (California) increased its AbbVie (ABBV) stake by 0.25% in Q1 2026, buying an estimated $9.98K and bringing the position to 18,130 shares worth $3.94M. The position accounts for 1.25% of the portfolio, ranked #25.

Spectrum Asset Management (California) first reported a position in ABBV in Q3 2018 and has held it in 31 quarters since. The position peaked at $4.76M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Spectrum Asset Management (California) held 18,130 shares of AbbVie worth $3.94M as of Q1 2026.
  • Spectrum Asset Management (California) bought 45 AbbVie shares in Q1 2026, an estimated $9.98K.
  • AbbVie made up 1.25% of Spectrum Asset Management (California)'s portfolio in Q1 2026, its #25 holding.
  • Spectrum Asset Management (California) first reported a position in AbbVie in Q3 2018 and has held it in 31 quarters since.
  • Spectrum Asset Management (California)'s AbbVie position peaked at $4.76M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Spectrum Asset Management (California)'s 13F filing for Q1 2026, filed 22 Apr 2026.